<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Academy of Kidney Cancer Investigators – Leadership Award | Academy Director and Deputy Director:  
- Supports established kidney cancer researchers with a record of mentoring junior faculty level kidney cancer scientists and/or clinicians.  
- Must have kidney cancer research funding (past and/or present); and a record of kidney cancer publications in peer-reviewed journals.  
- **Academy Director** - must be an independent and established kidney cancer investigator at or above the level of Associate Professor (or equivalent) as of the full application submission deadline.  
- **Deputy Director** - must be an independent kidney cancer researcher at the level of Associate Professor (or equivalent) as of the full application submission deadline and at a different institution from the Director. | • Must have vision and plan(s) of how Leadership team will empower Academy-Early Career Scholars to advance research and promote development as next generation of kidney cancer research leaders.  
• The Academy Director and Deputy Director (leadership) will lead the existing Academy of Early-Career Scholars and their Designated Mentor(s). The Academy consists of early career scientist/clinicians and their designated mentors.  
• Academy Director and Deputy Director will execute leadership/support, management plans, network opportunities, communication plans, assessments of research and career progression, and outline division of leadership team responsibilities for the Academy.  
• Clinical trials are not allowed.  
• Submission of a Letter of Intent is required prior to full application submission. | • Maximum funding of $1,500,000 for direct costs (plus indirect costs).  
• Maximum period of performance is 5 years.                                                                 | Pre-Application (Letter of Intent):  
August 29, 2024  
5:00 p.m. Eastern time  
Application:  
September 19, 2024  
11:59 p.m. Eastern time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Academy of Kidney Cancer Investigators – Early-Career Scholar Award | Investigators within 4 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline. *A letter attesting to eligibility required.* | *Supports addition of new Early-Career Scholars (ECS) to the unique, interactive virtual academy, which provides intensive mentoring, national networking, and a peer group for junior faculty.*  
*ECSs whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.*  
*Requires Designated Mentor who is an independent, established kidney cancer investigator with a record of kidney cancer publications in peer-reviewed journals.*  
*Designated Mentor not required to be at the same institution as the ECS.*  
*pPreliminary data are required.*  
*pFunding for clinical trials is not allowed.*  
*pSubmission of a Letter of Intent is required prior to full application submission.* | *The maximum allowable funding for the entire period of performance is $725,000 for direct costs.*  
*Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.*  
*The maximum period of performance is 4 years.* | Pre-Application (Letter of Intent): September 24, 2024  
5:00 p.m. Eastern time  
Application: October 15, 2024  
11:59 p.m. Eastern time |
| Grants.gov Funding Opportunity Number: HT942524KCRPAKCIIECSA               |                                                                              |                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                          |
| Clinical Trial Award                                 | Investigators at or above the level of Assistant Professor (or equivalent)   | *Supports hypothesis-based, early-phase clinical trials (e.g., phase 0, phase 1, pilot phase 2) to test interventions that will have a major impact in the field of kidney cancer.*  
*Interventions may include drugs, devices, biologics, surgical procedures, behavior modifications, or other types.*  
*Investigational New Drug or Investigational Device Exemption application(s), if applicable, must be submitted to the Food and Drug Administration by the Clinical Trial Award application submission deadline.*  
*Letter of support demonstrating proof of possession of sufficient drug supply to conduct study must be provided (if appropriate).*  
*Clinical trials are expected to be initiated within 12 months of the award date.*  
*Submission of a Letter of Intent is required prior to full application submission.* | *The maximum allowable funding for the entire period of performance is $1,500,000 for direct costs.*  
*Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.*  
*The maximum period of performance is 4 years.* | Pre-Application (Letter of Intent): September 24, 2024  
5:00 p.m. Eastern time  
Application: October 15, 2024  
11:59 p.m. Eastern time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Concept Award           | Investigators at all academic levels                                         | • Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.  
• Emphasis on innovation. 
• Funding for clinical trials is not allowed. 
• Preliminary data are not allowed and should not be submitted. 
• Blinded review.  
• Submission of a Letter of Intent is required prior to full application submission. | • The maximum allowable funding for the entire period of performance is $100,000 for direct costs. 
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 
• The maximum period of performance is 1 years.                                                                                           | Pre-Application (Letter of Intent): August 15, 2024  
5:00 p.m. Eastern time  
Application: September 5, 2024  
11:59 p.m. Eastern time |
| Idea Development Award  | Investigators at or above the level of Assistant Professor (or equivalent)  | • Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research and have the potential to make an important contribution to kidney cancer.  
• Preliminary data are required.  
• Innovation and impact are the most important review criteria.  
• Funding for clinical trials is not allowed.  
**Partnering Principal Investigator (PI) Option:**  
• Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.  
• The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project.  
• Applications where one PI is providing samples, animal models, or investigational agents while the other PI is conducting most or all of the experiments and analyses do not meet the intent of the Partnering PI Option.  
• Submission of a Letter of Intent is required prior to full application submission. | • The maximum allowable funding for the entire period of performance is $800,000 for direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is 4 years.  
**Partnering PI Option:**  
• The maximum allowable funding for the entire period of performance is $1,200,000 for direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is 4 years. | Pre-Application (Letter of Intent): September 24, 2024  
5:00 p.m. Eastern time  
Application: October 15, 2024  
11:59 p.m. Eastern time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Postdoctoral and Clinical Fellowship Award</strong></td>
<td>As of full application submission deadline, investigators:</td>
<td>• Supports research opportunities focused on kidney cancer for individuals in the early stages of their careers.</td>
<td>• The maximum allowable funding for the entire period of performance is <strong>$195,000</strong> for direct costs.</td>
<td>Pre-Application (Letter of Intent): August 15, 2024 5:00 p.m. Eastern time</td>
</tr>
<tr>
<td>Go to:</td>
<td>• Must possess a doctoral and/or medical degree (or equivalent).</td>
<td>• Requires participation of a Designated Mentor who is an experienced kidney cancer researcher.</td>
<td>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</td>
<td>Application: September 5, 2024 11:59 p.m. Eastern time</td>
</tr>
<tr>
<td></td>
<td>• Have 4 years or less of postdoctoral and/or mentored clinical research training experience (excluding family medical leave).</td>
<td><strong>Submission of a Letter of Intent is required prior to full application submission.</strong></td>
<td>• The maximum period of performance is 3 years.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>All other academic ranks are ineligible.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Grants.gov Funding Opportunity Number:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HT942524KCRPPCFA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Translational Research Partnership Award</strong></td>
<td>Investigators at or above the level of Assistant Professor (or equivalent).</td>
<td>• Supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer toward clinical applications.</td>
<td>• The maximum allowable funding for the entire period of performance is <strong>$750,000</strong> for direct costs.</td>
<td>Pre-Application (Letter of Intent): September 24, 2024 5:00 p.m. Eastern time</td>
</tr>
<tr>
<td>Go to:</td>
<td>One partner must have experience in kidney cancer or kidney cancer patient care.</td>
<td>• This award supports the development of translational research collaborations between two independent, faculty-level investigators to address a central problem or question in kidney cancer in a manner that would be less readily achievable through separate efforts.</td>
<td>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</td>
<td>Application: October 15, 2024 11:59 p.m. Eastern time</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research relevant to kidney cancer.</td>
<td>• The maximum period of performance is 3 years.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Supports translational correlative studies.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Preliminary data to support the feasibility of the research hypothesis(es) and research approaches are required; however, these data do not necessarily need to be derived from studies of kidney cancer.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Funding for clinical trials is not allowed.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Submission of a Letter of Intent is required. An invitation to submit a full application is not required.</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Grants.gov Funding Opportunity Number:**          |                                                                              |                                                                  |                                                                       |                                                          |
| HT942524KCRPTRPA                                    |                                                                              |                                                                  |                                                                       |                                                          |